A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Amedisys Inc (NASDAQ:AMED) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on January 16, 2018 and NASDAQ:AMED investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/15/2018 -- A deadline is coming up on January 16, 2018 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Amedisys Inc (NASDAQ:AMED) between August 2, 2005 and September 30, 2011.
Investors who purchased a significant amount of shares of Amedisys Inc (NASDAQ:AMED) between August 2, 2005 and September 30, 2011, have certain options and should contact the Shareholders Foundation by email at mail@shareholdersfoundation.com or call 858-779-1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the Amedisys Inc (NASDAQ:AMED) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/amedisys-inc-nasdaq-amed-investor-securities-class-action-lawsuit-06102010
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is January 16, 2018. The class action administrator for this case is A.B. Data Ltd.
The lawsuit was originally filed in the U.S. District Court for the Middle District of Louisiana against Amedisys Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between February 23, 2010 to May 13, 2010.
According to the complaint the plaintiff charges Amedisys Inc and certain of its officers and directors with violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint alleges that between February 23, 2010 and May 13, 2010 defendants issued materially false and misleading statements, as well as by failing to disclose material adverse facts about its business, operations, and prospects.
Those who purchased shares of Amedisys Inc (NASDAQ:AMED) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com